Here, we will introduce actions we are taking to fulfill our ideals.
01
MISSION/VISION 30
- From FY2021, we revamped the “Philosophy” to “MISSION” and formulated “VISION 30” as what we should like to be in 2030.
- We will be a healthcare company that delivers optimal therapy to each individual not only for treatment, but also for prevention, pre-symptomatic disease care, prevention of aggravation and prognosis.
02
Global business development
- Mitsubishi Tanabe Pharma began selling Radicava, our first new ALS medicine in 22 years, in the United States in August 2017.
- Began selling Exervan, Riluzole oral film following Radicava in the United States in July 2021.
- Began late-stage development in the United States and Europe of “dersimelagon”, world’s first oral Erythropoietic protoporphyria treatment by using know-how for rare disease.
03
Activities to fulfill precision medicine
- We defined precision medicine as “providing appropriate medical care to appropriate patients at appropriate timing”.
- We will reform the drug discovery process and increase open innovation in central nervous system and immuno-inflammation starting with Dersimelagon for prevention and treatment of Erythropoietic protoporphyria and Systemic sclerosis.
04
New challenges for
around the pill solutions
- Contribute to improving the quality of life of patients and their families by providing solutions based on therapeutic medicine from prevention to prognosis.
- By providing solutions that will establish new customer contact points, we will collect and analyze healthcare data.
05
R&D Policy
- By creating novel drugs which will be a solution for the unmet medical needs mainly in immuno-inflammation and central nervous system area continuously, we will enhance our presence.
- Development of precision medicine to increase patient satisfaction by precise analysis of the disease.
- Providing “Around the pill Solutions” by focusing on prevention, prevention of aggravation, and prognosis.
- Contribution to preventive medicine by vaccine development.
06
Awards Received for Drug Development
- Received the Pharmaceutical Society of Japan Award for Drug Research and Development four times.
- Received the 43rd Inoue Harushige Prize for research and development concerning Edaravone (US product name: Radicava®), a therapeutic agent for amyotrophic lateral sclerosis (ALS), in July 2018.
- Received the 3rd Japan Medical Research and Development Awards' Prime Minister Prize for research and development of Canagliflozin (Japan product name: Canaglu®), a therapeutic agent for type 2 diabetes, in January 2020.
07
Diverse Product Line
- Mitsubishi Tanabe Pharma has wide variety of medicinal drugs in four priority areas; autoimmune diseases, central nervous system diseases, diabetes and kidney diseases, and vaccines.
- We are making contribution to the society by creating many therapeutic agents that are the first of their kind, such as Imusera, Canaglu and Radicut.
08
Utilization of AI
- Mitsubishi Tanabe Pharma is optimizing clinical trials for new drug development by starting a collaboration with Hitachi, Ltd. that incorporates AI technology.
- We started our Zoom on Effective Ultimate System (ZEUS) digital marketing project, which aims to maximize the value of the information we supply to client physicians and to augment MR capabilities.
09
Tenohira Partnership Program
- We believe that, in addition to developing new drugs to treat incurable diseases, providing support for suffering patients and their families is an important mission. Accordingly, we established the Mitsubishi Tanabe Pharma Tenohira Partnership Program in 2012.
- Starting in fiscal 2013, we have been operating a program that offers grants to patient groups and support groups that aim to raise the quality of life of those who are suffering from incurable diseases.